Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy

被引:99
作者
Targher, G
Bertolini, L
Zoppini, G
Zenari, L
Falezza, G
机构
[1] Sacro Cuore Hosp, Dept Internal Med, Negrar, Italy
[2] Univ Verona, Div Endocrinol & Metab Dis, I-37100 Verona, Italy
关键词
endothelial dysfunction; microvascular complications; subclinical inflammation; Type; 1; diabetes;
D O I
10.1111/j.1464-5491.2005.01562.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate whether plasma biomarkers of inflammation and endothelial dysfunction differed in Type 1 diabetic patients as compared with those in non-diabetic subjects, and to examine the association of these biomarkers with early stages of microvascular complications. Methods Plasma biomarkers of inflammation [fibrinogen, hs-C-reactive protein (hs-CRP)] and endothelial dysfunction [von Willebrand factor (v-WF), intercellular adhesion molecule-1, plasminogen activator inhibitor-1 (PAI-1) activity] were measured in 88 non-smoking young patients with Type 1 diabetes without clinical macrovascular disease and in 40 healthy controls. Results Plasma levels of hs-CRP, fibrinogen, v-WF, soluble intracellular adhesion molecule-1 (sICAM-1) and PAI-1 activity were markedly higher (P < 0.01 or less) in Type 1 diabetic patients than in healthy controls; these results were essentially unchanged when healthy controls were compared with patients without complications. After stratification by microvascular complication status, plasma biomarkers of inflammation and endothelial dysfunction were significantly increased in those with more advanced disease compared with those with early complications or without complications, respectively. However, while the significant differences in these biomarkers were little affected by adjustment for sex, age, BMI and blood pressure values, they were totally abolished after additional adjustment for diabetes duration and glycaemic control. Conclusions These results indicate that in Type 1 diabetes there is a subclinical, chronic inflammation which is, at least partly, independent of clinically manifest macro- and microvascular complications, smoking or other traditional cardiovascular risk factors; this subclinical inflammation is closely correlated to the magnitude and duration of hyperglycaemia.
引用
收藏
页码:999 / 1004
页数:6
相关论文
共 26 条
[1]  
[Anonymous], 1991, Ophthalmology, V98, P786
[2]   Diabetes and endothelial dysfunction: A clinical perspective [J].
Calles-Escandon, J ;
Cipolla, M .
ENDOCRINE REVIEWS, 2001, 22 (01) :36-52
[3]  
Chakrabarti S, 2000, DIABETES-METAB RES, V16, P393, DOI 10.1002/1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO
[4]  
2-G
[5]   Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes - The EURODIAB Prospective Complications Study [J].
Chaturvedi, N ;
Sjoelie, AK ;
Porta, M ;
Aldington, SJ ;
Fuller, JH ;
Songini, M ;
Kohner, EM .
DIABETES CARE, 2001, 24 (02) :284-289
[6]   The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes [J].
Dandona, P ;
Aljada, A ;
Chaudhuri, A ;
Bandyopadhyay, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2422-2429
[7]   Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus [J].
Fasching, P ;
Veitl, M ;
Rohac, M ;
Streli, C ;
Schneider, B ;
Waldhausl, W ;
Wagner, OF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (12) :4313-4317
[8]   Fibrinogen and von Willebrand factor in IDDM: Relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: The EURODIAB IDDM complications study [J].
Greaves, M ;
Malia, RG ;
Goodfellow, K ;
Mattock, M ;
Stevens, LK ;
Stephenson, JM ;
Fuller, JH ;
Karamanos, B ;
Tountas, C ;
Kofinis, A ;
Petrou, K ;
Katsilambros, N ;
Giorgino, R ;
Cignarelli, M ;
DeCicco, ML ;
Ramunni, I ;
IonescuTirgoviste, C ;
Iosif, CM ;
Pitei, D ;
Buligescu, S ;
Tamas, G ;
Kerenyi, Z ;
Ahmed, AM ;
Toth, J ;
Kempler, P ;
Muntoni, S ;
Songini, M ;
Stabilini, M ;
Fossarello, M ;
Pintus, S ;
Ferriss, JB ;
Cronin, CC ;
Whyte, AE ;
Cleary, PE ;
Toeller, M ;
Klischan, A ;
Forst, T ;
Gries, FA ;
Rottiers, R ;
Priem, H ;
Ebeling, P ;
Sinisalo, M ;
Koivisto, VA ;
IdziorWalus, B ;
Solnica, B ;
SzopinskaCiba, L ;
Solnica, K ;
Krans, HMJ ;
Lemkes, HHPJ ;
Jansen, JJ .
DIABETOLOGIA, 1997, 40 (06) :698-705
[9]   Elevated C-reactive protein associates with early-stage carotid atherosclerosisis in young subjects with type 1 diabetes [J].
Hayaishi-Okano, R ;
Yamasaki, Y ;
Katakami, N ;
Ohtoshi, K ;
Gorogawa, S ;
Kuroda, A ;
Matsuhisa, M ;
Kosugi, K ;
Nishikawa, N ;
Kajimoto, Y ;
Hori, M .
DIABETES CARE, 2002, 25 (08) :1432-1438
[10]   Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders [J].
Hudson, BI ;
Bucciarelli, LG ;
Wendt, T ;
Sakaguchi, T ;
Lalla, E ;
Qu, W ;
Lu, Y ;
Lee, L ;
Stern, DM ;
Naka, Y ;
Ramasamy, R ;
Yan, SD ;
Yan, SF ;
D'Agati, V ;
Schmidt, AM .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) :80-88